Clinical Trials
Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.
Trial #:ACR-368-201
Sponsor: Acrivon Therapeutics, Inc/ GOG-3082
Trial Sub-Type: Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Title and Key Inclusion/Exclusion Criteria: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Trial #:AOA-PRT-0001
Sponsor: AOA Dx, Inc.
Trial Sub-Type: Suspicion, signs, or symptoms suggestive of ovarian cancer Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Title and Key Inclusion/Exclusion Criteria:Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Trial #: AVB500-OC-004 Now Enrolling
Sponsor: Aravive, Inc. / GOG 3059
Trial Sub-Type: Histologically confirmed recurrent ovarian, fallopian tube or peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are eligible; Prior treatment with 1-4 prior therapy regimens; Platinum-resistant disease (disease progression within 6 months of last platinum therapy).
Title and Key Inclusion/Exclusion Criteria: A Phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
Trial #: BP1001-A-101-GynOnc
Sponsor: Bio-Path Holdings, Inc
Trial Sub-Type: Recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube cancer
Title and Key Inclusion/Exclusion Criteria: BP1001-A-101-GynOnc: A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors.
Trial #: IMGN853-0416 GOG -3045
Trial Sub-Type: Confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer; Must have platinum-resistant disease (defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy); Patient’s tumor must be positive for FRα expression.
Title and Key Inclusion/Exclusion Criteria: A randomized, open-label, Phase 3 study of Mirvetuximab Soravtansine vs. Investigator’s Choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, Or fallopian tube cancers with high folate Receptor-alpha expression.
Trial #: MER-XM1536-1 Mersana Therapeutics, Inc. / GOG 3048 COMING SOON!
Trial Sub-Type: High grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent.
Title and Key Inclusion/Exclusion Criteria: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.
Trial #: Olvi-Vec-022
Sponsor: Genelux Corporation/ GOG 3076
Trial Sub-Type: Platinum-Resistant/Refractory Ovarian Cancer
Title and Key Inclusion/Exclusion Criteria: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer
Trial #: VB-111-701/GOG-3018
Sponsor: VBL Therapeutics/GOG
Trial Sub-Type: Recurrent Platinum-Resistant Ovarian
Title and Key Inclusion/Exclusion Criteria: The oval study: a randomized, controlled, double-arm, double-blind, multi-center study of Ofranergene Obadenovec (VB-111). Combined with Paclitaxel vs. Paclitaxel combined with placebo for the treatment of recurrent platinum-resistant ovarian cancer.